Innate Pharma (IPHA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.93 (+1.05%), Market cap $0.19B, 52-week low–high $1.17 ~ $2.38.
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive
Financial statements, price targets, institutional (13F) holdings and related news for Innate Pharma are updated in real time on BlackAll Trade.
Innate Pharma trades at $1.93 (+1.05%). Real-time quotes and charts are available on BlackAll Trade.
Innate Pharma has a market cap of about $0.19B.
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3